DOTATOC therapy belongs to the radiopeptide therapies. DOTATOC therapy exploits the property of tumors that express somatostatin receptors, as can occur, for example, in Meningiomas.
Administration
DOTATOC, also known as edotreotide, is an analogue of somatostatin that is conjugated to a radioactive nuclide, such as 90-yttrium, for therapy and subsequently administered intravenously. The therapy can be administered in several cycles.
Neurosurgical Relevance
DOTATOC therapy is used in neurosurgery, for example, in patients with aggressive meningioma courses that cannot be adequately treated surgically.